D

Dizal Jiangsu Pharmaceutical Co Ltd
SSE:688192

Watchlist Manager
Dizal Jiangsu Pharmaceutical Co Ltd
SSE:688192
Watchlist
Price: 45.1 CNY -3.34% Market Closed
Market Cap: 18.7B CNY
Have any thoughts about
Dizal Jiangsu Pharmaceutical Co Ltd?
Write Note
Dizal Jiangsu Pharmaceutical Co Ltd
/
Income Statement
/
Revenue

Dizal Jiangsu Pharmaceutical Co Ltd
Revenue

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
TTM
|

Dizal Jiangsu Pharmaceutical Co Ltd
Revenue Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Revenue CAGR 3Y CAGR 5Y CAGR 10Y
D
Dizal Jiangsu Pharmaceutical Co Ltd
SSE:688192
Revenue
¥91.3m
CAGR 3-Years
49%
CAGR 5-Years
18%
CAGR 10-Years
N/A
Beigene Ltd
HKEX:6160
Revenue
¥17.4B
CAGR 3-Years
102%
CAGR 5-Years
68%
CAGR 10-Years
N/A
Beijing Wantai Biological Pharmacy Enterprise Co Ltd
SSE:603392
Revenue
¥5.5B
CAGR 3-Years
33%
CAGR 5-Years
41%
CAGR 10-Years
N/A
Shanghai RAAS Blood Products Co Ltd
SZSE:002252
Revenue
¥8.3B
CAGR 3-Years
37%
CAGR 5-Years
31%
CAGR 10-Years
27%
Chongqing Zhifei Biological Products Co Ltd
SZSE:300122
Revenue
¥46.7B
CAGR 3-Years
30%
CAGR 5-Years
42%
CAGR 10-Years
51%
Imeik Technology Development Co Ltd
SZSE:300896
Revenue
¥2.9B
CAGR 3-Years
59%
CAGR 5-Years
55%
CAGR 10-Years
N/A
No Stocks Found

Dizal Jiangsu Pharmaceutical Co Ltd
Glance View

Market Cap
18.4B CNY
Industry
Biotechnology

Dizal (Jiangsu) Pharmaceutical Co., Ltd. engages in the discovery, development, and commercialization of innovative medicines. The company is headquartered in Shanghai, Shanghai and currently employs 328 full-time employees. The company went IPO on 2021-12-10. The firm focuses on diseases such as malignant tumors and immune diseases. The main candidate innovative drugs in the Company's research and development (R&D) pipeline are DZD4205, DZD9008, DZD1516, DZD2269, DZD8586, DZD0095. The firm is still in the R&D stage.

Intrinsic Value
30.31 CNY
Overvaluation 33%
Intrinsic Value
Price
D
What is Intrinsic Value?

See Also

What is Dizal Jiangsu Pharmaceutical Co Ltd's Revenue?
Revenue
91.3m CNY

Based on the financial report for Dec 31, 2023, Dizal Jiangsu Pharmaceutical Co Ltd's Revenue amounts to 91.3m CNY.

What is Dizal Jiangsu Pharmaceutical Co Ltd's Revenue growth rate?
Revenue CAGR 5Y
18%

The average annual Revenue growth rates for Dizal Jiangsu Pharmaceutical Co Ltd have been 49% over the past three years , 18% over the past five years .

Back to Top
ALPHA SPREAD
Follow us
Join more than 201,200+ value investors using Alpha Spread
Create a free account
or see our plans & pricing

Company

About Us Careers Pricing Affiliate Program Terms of Service Privacy Policy

Help

What is Intrinsic Value? Help Center Contact Us

Tools

Stock Screener Intrinsic Value Calculator DCF Value Calculator Discount Rate Calculator

Stocks

Most Undervalued Stocks Wide Economic Moat Stocks High Profitability Stocks High Solvency Stocks Most Popular Stocks

© 2024 Alpha Spread Limited. All Rights Reserved.

www.alphaspread.com is not operated by a broker, a dealer, or a registered investment adviser. Under no circumstances does any information posted on www.alphaspread.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute, investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. In no event shall Alpha Spread Limited be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on www.alphaspread.com, or relating to the use of, or inability to use, www.alphaspread.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance.